ORL-1 Agonist Therapy for Afferent Overactive Bladder Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for overactive bladder syndrome (OBS) primarily focus on inhibiting the efferent pathway associated with muscle contraction, while there is a need for effective treatments targeting the sensory (afferent) pathways using small-molecule therapeutics that can be orally administered.
Innovation Solution
Administration of a small-molecule agonist of the nociception opioid peptide receptor (ORL-1 receptor) to modulate afferent nerve activity in the lower urinary tract, thereby treating or preventing OBS and associated symptoms such as urinary incontinence, urgency, and nocturia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antimuscarinic agents are administered to block efferent pathway, then muscle contraction is inhibited and urination is prevented, but treatments affecting sensory (afferent) pathways have less success
Solution Approach 1:
The patent segments the treatment approach by specifically targeting the afferent sensory pathway (via ORL-1 receptor agonism) rather than the traditional efferent motor pathway. This segmentation allows the treatment to address the sensory component of overactive bladder syndrome that was previously overlooked, thereby improving overall treatment effectiveness while expanding pathway coverage.
Solution Approach 2:
Instead of continuing to block the efferent pathway as conventional treatments do, the patent inverts the approach by activating the ORL-1 receptor on afferent nerves to reduce sensory signaling. This inverted strategy of targeting the sensory input rather than the motor output represents a fundamental shift in treatment methodology.
2Ease of operation
If small-molecule therapeutics are developed for oral administration, then ease of administration is improved, but there is a need for effective treatments targeting afferent pathways
Solution Approach 1:
The patent employs small-molecule therapeutics as intermediaries that can orally cross the blood-brain barrier and selectively activate ORL-1 receptors on afferent nerves in the lower urinary tract. These small molecules serve as effective mediators that bridge the gap between oral administration convenience and targeted afferent pathway modulation, achieving both ease of operation and treatment reliability.
3Reliability
If ORL-1 receptor agonist is administered to reduce bladder contractions, then pressure threshold for miction is increased and contraction frequency decreases, but side effects may occur
Solution Approach 1:
The patent achieves local quality by selectively targeting ORL-1 receptors on afferent nerves within the lower urinary tract, rather than producing systemic effects throughout the body. This localized action at the site of pathology maximizes therapeutic benefit while minimizing side effects, as the agonist primarily affects the bladder and surrounding afferent pathways.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ORL-1 receptor agonist effectively reduces bladder contractions, increases pressure threshold for micturition, decreases contraction frequency of the detrusor muscle, and alleviates symptoms like urinary incontinence and nocturia, providing a therapeutic benefit without significant side effects.
Implementation Method 1
Administration of a small-molecule agonist of the nociception opioid peptide receptor (ORL-1 receptor) to modulate afferent nerve activity in the lower urinary tract
Data Source
AI summary
The disclosure provides a method of treating or preventing overactive bladder syndrome (OBS) in a human subject (with normal renal function, mild renal impairment, or mild to moderate renal impairment) in need of such treatment, comprising administering to the human subject a therapeutically effective amount of a compound of the formula (I) or a pharmaceutically acceptable salt thereof. In one embodiment, the method comprises administering the compound of formula (IA).